Gene Therapy in Cancer Treatment: Why Go Nano?
The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/3/233 |
| _version_ | 1818036783540076544 |
|---|---|
| author | Catarina Roma-Rodrigues Lorenzo Rivas-García Pedro V. Baptista Alexandra R. Fernandes |
| author_facet | Catarina Roma-Rodrigues Lorenzo Rivas-García Pedro V. Baptista Alexandra R. Fernandes |
| author_sort | Catarina Roma-Rodrigues |
| collection | DOAJ |
| description | The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications. |
| first_indexed | 2024-12-10T07:16:26Z |
| format | Article |
| id | doaj.art-12e300fc23264b8eac74271ecce6c2f0 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-12-10T07:16:26Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-12e300fc23264b8eac74271ecce6c2f02022-12-22T01:57:55ZengMDPI AGPharmaceutics1999-49232020-03-0112323310.3390/pharmaceutics12030233pharmaceutics12030233Gene Therapy in Cancer Treatment: Why Go Nano?Catarina Roma-Rodrigues0Lorenzo Rivas-García1Pedro V. Baptista2Alexandra R. Fernandes3UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, PortugalUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, PortugalUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, PortugalUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, PortugalThe proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.https://www.mdpi.com/1999-4923/12/3/233gene therapygene deliverytumor microenvironmentnanoparticlesnanomedicine |
| spellingShingle | Catarina Roma-Rodrigues Lorenzo Rivas-García Pedro V. Baptista Alexandra R. Fernandes Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics gene therapy gene delivery tumor microenvironment nanoparticles nanomedicine |
| title | Gene Therapy in Cancer Treatment: Why Go Nano? |
| title_full | Gene Therapy in Cancer Treatment: Why Go Nano? |
| title_fullStr | Gene Therapy in Cancer Treatment: Why Go Nano? |
| title_full_unstemmed | Gene Therapy in Cancer Treatment: Why Go Nano? |
| title_short | Gene Therapy in Cancer Treatment: Why Go Nano? |
| title_sort | gene therapy in cancer treatment why go nano |
| topic | gene therapy gene delivery tumor microenvironment nanoparticles nanomedicine |
| url | https://www.mdpi.com/1999-4923/12/3/233 |
| work_keys_str_mv | AT catarinaromarodrigues genetherapyincancertreatmentwhygonano AT lorenzorivasgarcia genetherapyincancertreatmentwhygonano AT pedrovbaptista genetherapyincancertreatmentwhygonano AT alexandrarfernandes genetherapyincancertreatmentwhygonano |